Page last updated: 2024-10-22

antipyrine and Nasopharyngitis

antipyrine has been researched along with Nasopharyngitis in 1 studies

Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.

Nasopharyngitis: Inflammation of the NASOPHARYNX, usually including its mucosa, related lymphoid structure, and glands.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2[NCT01492686]			Phase 3	137 participants (Actual)	Interventional	2011-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks

(NCT01492686)
Timeframe: baseline and 24 weeks

Intervention	percentage of FVC (Least Squares Mean)
MCI-186	-15.61
Placebo of MCI-186	-20.4

Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks

The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, Activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. 200=worst; 40=best (NCT01492686)
Timeframe: baseline and 24 weeks

Intervention	units on a scale (Least Squares Mean)
MCI-186	17.25
Placebo of MCI-186	26.04

Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks

The Modified Norris Scale is a measure of movement disorder for patients with ALS. 0=worst; 102=best (NCT01492686)
Timeframe: baseline and 24 weeks

Intervention	units on a scale (Least Squares Mean)
MCI-186	-15.91
Placebo of MCI-186	-20.8

Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks

0=worst; 48=best (NCT01492686)
Timeframe: baseline and 24 weeks

Intervention	units on a scale (Least Squares Mean)
MCI-186	-5.01
Placebo of MCI-186	-7.5

Percentage of Participants With Adverse Drug Reactions

(NCT01492686)
Timeframe: 24 weeks

Intervention	percentage of Participants (Number)
MCI-186	2.9
Placebo of MCI-186	7.4

Percentage of Participants With Adverse Events

(NCT01492686)
Timeframe: 24 weeks

Intervention	percentage of Participants (Number)
MCI-186	84.1
Placebo of MCI-186	83.8

"Laboratory Tests Percentage of Participants With Adverse Events by System Organ Class (SOC) of Investigations (PT, MedDRA Ver. 17.0)"

(NCT01492686)
Timeframe: 24 weeks

Intervention	percentage of Participants (Number)
	Blood bilirubin increased	Blood creatine phosphokinase increased	Liver function test abnormal	White blood cell count decreased
MCI-186	0	0	1.4	1.4
Placebo of MCI-186	1.5	1.5	1.5	0

Number of Participants With Death or a Specified State of Disease Progression

"Any of death, disability of independent ambulation, loss of upper limbs function, tracheotomy, use of respirator, use of tube feeding and loss of useful speech was defined as an event." (NCT01492686)
Timeframe: 24 weeks

Intervention	Count of Participants (Number)
	Death	Disability of independent ambulation	Loss of upper limbs function	Tracheotomy	Use of respirator	Use of tube feeding	Loss of useful speech
MCI-186	0	0	0	1	0	0	1
Placebo of MCI-186	0	2	0	0	0	1	3

Percentage of Participants With Abnormal Values in Sensory Examinations

(NCT01492686)
Timeframe: baseline and 24 weeks

Intervention	percentage of Participants (Number)
	Numbness (at baseline)	Numbness (at 24 week)	Staggering (at baseline)	Staggering (at 24 week)
MCI-186	2.9	7.2	1.4	2.9
Placebo of MCI-186	7.4	9.4	8.8	3.1

Trials

1 trial available for antipyrine and Nasopharyngitis

Article	Year
Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis & frontotemporal degeneration, 2017, Volume: 18, Issue:sup1 Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free	2017